Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06269874 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Comparing Two Administration Pathways for Adenosine During Microvascular Function Assessment

Study acronym: ASPERA-ANOCA
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 31, 2024 to Jul 31, 2027
    • Start date: Mar 2, 2024 to Mar 2, 2027
    • Study completion date: Aug 31, 2024 to Aug 31, 2027
    v3
  2. Interventions: Microvascular function assessment (Diagnostic Test) to microvascular function assessment (Diagnostic Test)
    • Eligibility criteria expanded, about 8 words
    • Study description expanded, about 2 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to investigate the agreement and reproducibility between intravenous and intracoronary adenosine administration during invasive assessment of microvascular function. Goals of this study are: 1. Agreement and reproducibility between intravenous and intracoronary adenosine administration in the IMR (Index of microvascular resistance) value. 2. Agreement and reproducibility of FFR(fractional flow reserve), CFR (coronary flow reserve), MRR (microvascular resistance reserve), RRR (resistive reserve ratio) and reproducibility of each of these as compared with CFRabs (absolute coronary flow). 3. Time required for IMR measurements
Trial Details
NCT Number NCT06269874
Lead Sponsor Johannes Gutenberg University Mainz
Conditions
(from sponsor)		 Microvascular Coronary Artery Disease
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov